A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01071252 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Plaque-type Psoriasis

Interventions

DRUG: AIN457
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals